Search results for "Stem Cell"

showing 10 items of 2354 documents

Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results…

2015

Beyond hemoglobin (Hb) levels and performance status, further surrogate markers of appropriate transfusion management should improve the quality of thalassemia care. We investigated the levels of peripheral circulating CD34+ stem cells as an independent marker of appropriate hematopoietic balance in patients with thalassemia.Peripheral circulating CD34+ stem cells, colony-forming unitgranulocyte, erythrocyte, macrophage, magakaryocyte (CF-GEMM), colony-forming unitgranulocyte/macrophage (CFU-GM), and erythroidburst-forming units (BFU-E) were assayed, according to standard procedures. Patients with thalassemia major (TM) and thalassemia intermedia (TI) were tested and compared to healthy con…

AdultMaleAdolescentbeta-ThalassemiaHematopoietic Stem Cell TransplantationPilot ProjectsMiddle AgedHematopoietic Stem CellsPrognosisSettore MED/15 - Malattie Del SangueYoung AdultPeripheral CD34+ stem cells beta-thalassemiaTreatment OutcomeCase-Control StudiesHumansFemaleBiomarkersAgedFollow-Up Studies
researchProduct

Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.

2016

We investigated a possible interaction between age-associated risk and HLA-mismatch associated risk on prognosis in different age categories of recipients of unrelated hematopoietic stem cell transplants (HSCT) (n=3019). Patients over 55 years of age transplanted with 8/10 donors showed a mortality risk of 2.27 (CI 1.70–3.03, P<0.001) and 3.48 (CI 2.49–4.86, P<0.001) when compared to 10/10 matched patients in the same age group and to 10/10 matched patients aged 18–35 years, respectively. Compared to 10/10 matched transplantations within each age category, the Hazards Ratio for 8/10 matched transplantation was 1.14, 1.40 and 2.27 in patients aged 18–35 years, 36–55 and above 55 years. Model…

AdultMaleAdolescentmedicine.medical_treatmentAge categoriesHematopoietic stem cell transplantationHuman leukocyte antigenHistocompatibility TestingKaplan-Meier Estimate03 medical and health sciencesYoung Adult0302 clinical medicineHLA AntigensRisk FactorsCell Therapy & ImmunotherapymedicineHumansPublic Health SurveillanceYoung adultMortalityAgedbusiness.industryHistocompatibility TestingAge FactorsHematopoietic Stem Cell TransplantationHematopoietic stem cellHematologyArticlesMiddle Aged3. Good healthHistocompatibilitysurgical procedures operativemedicine.anatomical_structure030220 oncology & carcinogenesisHistocompatibilityImmunologyFemalebusinessUnrelated Donors030215 immunologyHaematologica
researchProduct

Bone marrow after autologous blood stem cell transplantation and total body irradiation: magnetic resonance and chemical shift imaging.

1993

Magnetic resonance studies of the lumbar, pelvic, and femoral bone marrow were performed in 10 patients after autologous blood stem cell transplantation, including total body irradiation and myeloablative chemotherapy. The posttreatment interval varied between 2 and 6 yr. The appearance on T1-weighted images and the quantitative data obtained from chemical shift imaging (relative fat signal) were compared to 10 age-matched healthy volunteers. The classification of the T1-weighted images yielded no significant differences between the two groups. Chemical shift imaging by determination of the relative fat signal was able to detect a significant fatty replacement of the patients' lumbar (p < .…

AdultMaleAdolescentmedicine.medical_treatmentBiomedical EngineeringBiophysicsBlood cellLumbarBone MarrowmedicineHumansRadiology Nuclear Medicine and imagingFemurChildPelvic BonesChemotherapyLeukemiaLumbar Vertebraemedicine.diagnostic_testChemistrybusiness.industryHematopoietic Stem Cell TransplantationMagnetic resonance imagingTotal body irradiationMiddle AgedCombined Modality TherapyMagnetic Resonance ImagingTransplantationmedicine.anatomical_structureAcute DiseaseFemaleBone marrowStem cellNuclear medicinebusinessWhole-Body IrradiationMagnetic resonance imaging
researchProduct

Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC …

1998

Despite the wide use of G-CSF for mobilization of PBPC the best dose and schedule of G-CSF has not been definitively established. In this study we have compared three different schedules of G-CSF for mobilization of PBPC in normal donors including a single daily dose of 10 microg/kg/day for 5 days (21 donors) and doses of 6 (21 donors) or 8 microg/kg/12 h (6 donors) for 5 days. We demonstrate that G-CSF at doses of 6 and 8 microg/kg/12 h mobilizes significantly more CD34+ cells/ml of blood (83.3 +/- 6.7 and 121 +/- 6.9, respectively) than 10 microg/kg/day (71.6 +/- 6.5). Mobilization with 6 or 8 microg/kg/12 h of G-CSF was also associated with collection of significantly more CD34+ cells in…

AdultMaleAdolescentmedicine.medical_treatmentBlood volumeHematopoietic stem cell transplantationDrug Administration ScheduleAndrologyGranulocyte Colony-Stimulating FactorHumansTransplantation HomologousMedicinePlateletProgenitor cellChildAgedTransplantationMobilizationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell MobilizationBlood Cell CountGranulocyte colony-stimulating factorTransplantationmedicine.anatomical_structureImmunologyBlood Component RemovalFemaleBone marrowbusinessBone Marrow Transplantation
researchProduct

Influence of oral health on mucositis in patients undergoing hematopoietic progenitor cell transplantation (HPCT).

2010

Aims: To establish whether or not the state of patient oral health can influence the occurrence and/or severity of oral mucositis during hematopoietic progenitor cell transplantation (HPCT). Materials and Methods: The study included 72 patients awaiting HPCT. Prior to transplantation, clinical exploration and radiology were carried out and oral photographs were taken. This evaluated the extent of caries present, the number of missing teeth and the number of dental fillings in each patient; CAO (Caries and Obturations Index) DMFS (Decayed, Missing, and Filled Surfaces) and Restoration Indices were calculated. Gingival pathology was also examined by means of the Ainamo and Bay Gingival Bleedi…

AdultMaleAdolescentmedicine.medical_treatmentDentistryOral HealthHematopoietic stem cell transplantationOral healthOral hygieneSeverity of Illness IndexYoung AdultSeverity of illnessmedicineMucositisHumansYoung adultChildGeneral DentistryStomatitisAgedStomatitisbusiness.industryHematopoietic Stem Cell TransplantationMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Transplantationstomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryFemaleResearch-ArticleOdontostomatology for the Disabled or Special PatientsbusinessMedicina oral, patologia oral y cirugia bucal
researchProduct

Age-Related Lipid Metabolic Signature in HumanLMNA-Lipodystrophic Stem Cell-Derived Adipocytes

2015

Lamin A (LMNA)-linked lipodystrophies belong to a group of clinical disorders characterized by a redistribution of adipose tissue with a variable range of metabolic complications. The leading cause of these disorders is the nonphysiological accumulation of the lamin A precursor, prelamin A. However, the molecular mechanisms by which prelamin A induces the pathology remain unclear.The aim of this study is to use an experimental LMNA-lipodystrophy model based on human mesenchymal stem cell (hMSC)-derived adipocytes that accumulate prelamin A to gain deeper insights into the mechanisms governing these diseases.Prelamin A-induced or -noninduced hMSC-derived adipocytes were obtained from healthy…

AdultMaleAgingcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAdolescentLipodystrophyLipolysisEndocrinology Diabetes and MetabolismCellular differentiationClinical BiochemistryAdipose tissueMitochondrionBiologyBiochemistryLMNAYoung AdultEndocrinologyInternal medicineAdipocytesmedicineHumansMetabolomicsLipolysisintegumentary systemStem CellsBiochemistry (medical)Mesenchymal stem cellnutritional and metabolic diseasesCell DifferentiationMiddle AgedLamin Type ALipid MetabolismEndocrinologyMetabolomeFemaleStem cellLaminThe Journal of Clinical Endocrinology &amp; Metabolism
researchProduct

Busulfan systemic exposure after oral administration of extemporeanously prepared high-dose busulfan capsules.

2009

Purpose. The aim of the study was to analyze patients’ busulfan (BU) exposure after oral administration of extemporeanously prepared BU capsules prior to blood stem cell transplantation. Methods. Patients were treated with 1 mg/kg body weight BU administered orally every 6h on each of 4 consecutive days prior to blood stem cell transplantation. Each BU dose was administered in 1 gelatine capsule to be swallowed and containing the individually calculated dose of pure BU active substance. Blood samples were obtained from 6 adult patients 0, 30, 60, 90, 120, 180, 240, 300, and 360 min after the 1st, 5th, and 13th BU dose, frozen and analyzed subsequently by using a HPLC assay with UV detectio…

AdultMaleAlkylating AgentsTransplantation ConditioningDrug CompoundingAdministration OralCapsulesPharmacologyHplc assayPharmacokineticsOral administrationMedicineHumansPharmacology (medical)BusulfanCyclophosphamideChromatography High Pressure LiquidPeripheral Blood Stem Cell Transplantationmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryCapsuleMiddle AgedTransplantationOncologyTherapeutic drug monitoringConcomitantArea Under CurveDrug Therapy CombinationFemaleSpectrophotometry UltravioletDrug MonitoringbusinessBusulfanmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

Temporal dynamics of hippocampal neurogenesis in chronic neurodegeneration.

2014

Increased neurogenesis has been reported in neurodegenerative disease, but its significance is unclear. In a mouse model of prion disease, Gomez-Nicola et al. detect increased neurogenesis in the dentate gyrus that partially counteracts neuronal loss. Targeting neurogenesis may have therapeutic potential.

AdultMaleAntimetabolites AntineoplasticPatch-Clamp TechniquesTime FactorsPrionsNeurogenesisGenetic VectorsHippocampusTissue BanksBiologyHippocampal formationHippocampusCreutzfeldt-Jakob SyndromePrion DiseasesMiceYoung AdultNeural Stem CellsAlzheimer Diseasevariant CJDNeural PathwaysmedicineAnimalsHumansAgedCell ProliferationDentate gyrusNeurogenesisNeurodegenerationCytarabineNeurodegenerative DiseasesOriginal ArticlesMiddle Agedmedicine.diseaseNeural stem cellMice Inbred C57BLNeuroanatomical Tract-Tracing Techniquesadult neurogenesisDisease Models AnimalChronic DiseaseDentate GyrusMossy Fibers HippocampalDisease ProgressionFemaleNeurology (clinical)Alzheimer's diseaseNeuroscienceNeural developmentAlzheimer’s diseaseBrain : a journal of neurology
researchProduct

A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acut…

2013

Unlike cytarabine, cellular entry of Elacytarabine, the elaidic acid ester derivative of cytarabine, is independent of the human equilibrative nucleoside transporter 1 (hENT1). This phase II study tested whether the hENT1 blast expression level can be used as a predictive marker for cytarabine response and if the efficacy of elacytarabine is independent of hENT1 expression. A total of 51 patients with acute myeloid leukemia (AML) induction failure were given elacytarabine-idarubicin as a second induction course. The hENT1 expression level was analyzed prior to first induction and/or prior to treatment with elacytarabine. The overall response rate (ORR) was 41% and the safety profile was man…

AdultMaleCancer ResearchAdolescentPhases of clinical researchGene ExpressionPharmacologyNucleoside transporterEquilibrative nucleoside transporter 1Equilibrative Nucleoside Transporter 1Young AdultBone MarrowAntineoplastic Combined Chemotherapy ProtocolsmedicineIdarubicinHumansAgedPredictive markerbiologyElacytarabinebusiness.industryCytarabineHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyInduction ChemotherapyMiddle AgedLeukemia Myeloid AcuteTreatment OutcomeOncologybiology.proteinCytarabineFemalebusinessIdarubicinmedicine.drugLeukemialymphoma
researchProduct

Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.

2008

Therapeutic effects of haematopoietic stem cell transplantation are not limited to maximal chemoradiotherapy and subsequent bone marrow regeneration, but include specific as well as unspecific immune reactions known as graft-versus-leukaemia (GvL) effects. Specific immune reactions are likely to be particularly relevant to the long-term treatment of diseases, such as chronic myeloid leukaemia (CML), in which residual cells may remain quiescent and unresponsive to cytotoxic and molecular therapies for long periods of time. Specific GvL effects result from the expression on leukaemic cells of specific tumour-associated antigens (TAAs) in the context of HLA proteins. As human leukocyte antigen…

AdultMaleCancer ResearchDNA ComplementaryT-LymphocytesAntigen-Presenting CellsEnzyme-Linked Immunosorbent AssayHuman leukocyte antigenBiologyAntigenhemic and lymphatic diseasesLeukemia Myelogenous Chronic BCR-ABL PositivemedicineCytotoxic T cellHumansIn Situ Hybridization FluorescenceReverse Transcriptase Polymerase Chain ReactionHematologyNM23 Nucleoside Diphosphate Kinasesmedicine.diseaseTransplantationHaematopoiesismedicine.anatomical_structureOncologyImmunologyBone marrowStem cellChronic myelogenous leukemiaLeukemia
researchProduct